Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06252519 · ClinicalTrials.gov registry record · NA
Pharmacokinetic Profile of N-Acetyl Cysteine
A NA study of Pharmacokinetics, sponsored by University of Memphis.
- Completed
- Registry status
- NA
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT06252519: Completed NA study of Pharmacokinetics, sponsored by University of Memphis.
NCT06252519 is a NA study of Pharmacokinetics that has completed, run by University of Memphis. The registered enrollment target is 8 participants, below the 62-participant average among 37 other Pharmacokinetics trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06252519, a NA study of Pharmacokinetics, has completed, sponsored by University of Memphis.
- COMPLETED
- Registry status
- NA
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
The study compares three different formulations containing N-Acetyl Cysteine, with regards to acute absorption over a 24-hour period, following single ingestion. The formulations are traditional N-Acetyl Cysteine, N-Acetyl Cysteine Ethyl Ester, and a product containing a combination of N-Acetyl Cysteine Ethyl Ester, glycine, and two minerals with antioxidant potential (selenium and molybdenum) that might enhance the effect of N-Acetyl Cysteine Ethyl Ester. Subjects will report to the lab on three different occasions to consume the products, using a randomized cross-over design, and blood will be collected periodically (for the initial 8 hours and then again at 24 hours) per standard, routinely used pharmacokinetic /pharmacodynamic study protocols for evaluation of circulating glutathione concentrations. The hypothesis for this study is that the combination of N-Acetyl Cysteine Ethyl Ester + glycine will yield the greatest increase in glutathione, followed by N-Acetyl Cysteine Ethyl Ester, followed by N-Acetyl Cysteine. These findings will provide initial evidence specific to the bioavailability of these treatments following a single acute ingestion and may guide future recommendations regarding routine use.
Primary Outcome
The area under the concentration curve for reduced glutathione over oxidized glutathione will be calculated for each supplement.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT NAC
- DIETARY_SUPPLEMENT Neuro-NAC
- DIETARY_SUPPLEMENT Neuro-NAC XS
Study Locations (1)
Tennessee
- Center for Nutraceutical and Dietary Supplement Research - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2023-09-18 |
| Est. Completion | 2024-05-22 |
| Phase | NA |
What the finished NCT06252519 record still lists
NCT06252519 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 62-participant average among 37 other Pharmacokinetics trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Pharmacokinetics appearing as the primary indexed condition, and to 3 interventions - of which NAC is the first listed.
NCT06252519 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT06252519 about?
NCT06252519 is a clinical study titled "Pharmacokinetic Profile of N-Acetyl Cysteine". The study compares three different formulations containing N-Acetyl Cysteine, with regards to acute absorption over a 24-hour period, following single ingestion. The formulations are traditional N-Acetyl Cysteine, N-Acetyl Cysteine Ethyl Ester, and a product containing a combination of N-Acetyl Cyst...
What is the current status of trial NCT06252519?
This trial is currently completed. It is a NA study. The enrollment target is 8 participants. The study started on 2023-09-18. Estimated completion is 2024-05-22.
What conditions does trial NCT06252519 study?
This clinical trial studies the following conditions: Pharmacokinetics.
What interventions are being tested in trial NCT06252519?
The interventions under investigation include: NAC (DIETARY_SUPPLEMENT), Neuro-NAC (DIETARY_SUPPLEMENT), Neuro-NAC XS (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06252519?
This trial is sponsored by University of Memphis, which has 35 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06252519 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pharmacokinetics
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06252519's enrollment target sits among peer trials
8 35th of 37 higher than 3 of 37 other Pharmacokinetics trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pharmacokinetics trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Interaction Between Cannabidiol, Meal Ingestion, and Liver Function
COMPLETED · NA
-
Pharmacokinetics of Two Fatty Acid Ketone Esters
COMPLETED · NA
-
Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
High Potency Cannabis: Acute and Protracted Effects
RECRUITING · Phase 1
-
Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose
RECRUITING · Phase 1
-
Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI